Key clinical point: Upfront treatment with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab “significantly and meaningfully” improves overall survival in metastatic colorectal cancer when compared with chemotherapy doublets plus bevacizumab.
Major finding: There was a 4.4-month increase in median overall survival and an 11.6% increase in estimated 5-year overall survival with FOLFOXIRI plus bevacizumab.
Study details: An analysis of 1,697 patients pooled from five clinical trials.
Disclosures: There was no external funding for the analysis, but some of the original trials were sponsored by Roche. The lead author disclosed ties with Roche and other companies.
Cremolini C et al. J Clin Oncol. 2020 Aug 20. doi: 10.1200/JCO.20.01225.